Grant: Alliance Grants
Université Laval
$49,650.00
Refining preclinical tools in lung physiology to evaluate COVID-19-mediated deaths from respiratory failure_x000d_ _x000d_ _x000d_ _x000d_ _x000d_
EF 2020-21
Résumé
What is the nature of the work? Since 70 percent of COVID-19-related deaths are attributed to respiratory failure, mouse models of respiratory failure will become increasingly employed to test promising drugs. The measurement of lung physiology in an animal as small as a mouse will also become paramount. Although this represents a huge engineering challenge, it has already been overcome by SCIREQ, a Canadian company that has created a device called the flexiVent. The flexiVent is still underused in research on respiratory failure and, owing to its growing versatility, its integration in this new specific field will require extensive procedural troubleshooting in order to optimize the outcomes. The goal of the present project is to develop a standardized and fully automated protocol that will provide the most comprehensive evaluation of lung physiology in a murine model of respiratory failure.
To whom the research is important? Our protocol will entitle non-respiratory experts to readily measure lung physiology with minimal mouse handling. On the short term, our project is thus essential for scientists who are specialized in the molecular and cellular aspects of infectious diseases but who need assistance to measure lung physiology in mice. On the long term, our project has the potential to improve patients' care and save lives by accelerating research and drug discovery on COVID-19
What are the anticipated outcomes and advancements that will result in benefits for Canada? A landmark protocol such as the one we aim to develop will ensure accuracy and reproducibility of the collected data. It will also facilitate comparisons between the tested drugs and the different laboratories. Additionally, it will promote a mature technology of a Canadian company, strengthen the link between an academic and a private sector, train highly qualified personnel and keep Canadian lung physiologists at the leading-edge of their field.
_x000d_Quelle est la nature du travail? Étant donné que 70% de la mortalité reliée à la COVID-19 est attribuée à une insuffisance respiratoire, les modèles murins d'insuffisance respiratoire deviendront de plus en plus utilisés afin de tester des drogues promett
Programme
Alliance Grants
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
553984-2020
Name nom
Bossé, Ynuk
Department département
Médecine
Organization id
51
Institution établissement
Université Laval
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2020
Competition year année de concours
2020
Award amount
49650
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
518
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Medical equipment and apparatus
Area of application fr
Appareils et instruments médicaux
Research subject code
6400
Research subject group en
Life sciences research related to human health and disease
Research subject group fr
Sciences de la vie liées à la santé publique et aux maladies humaines
Research subject en
Life sciences research related to human health and disease
Research subject fr
Sciences de la vie liées à la santé publique et aux maladies humaines
Installment
inst:1 - 1
Partie
1
Nb partie
1
Application title
Refining preclinical tools in lung physiology to evaluate COVID-19-mediated deaths from respiratory failure_x000d_
_x000d_
_x000d_
_x000d_
_x000d_
Keyword
NSERC
Application summary
What is the nature of the work? Since 70 percent of COVID-19-related deaths are attributed to respiratory failure, mouse models of respiratory failure will become increasingly employed to test promising drugs. The measurement of lung physiology in an animal as small as a mouse will also become paramount. Although this represents a huge engineering challenge, it has already been overcome by SCIREQ, a Canadian company that has created a device called the flexiVent. The flexiVent is still underused in research on respiratory failure and, owing to its growing versatility, its integration in this new specific field will require extensive procedural troubleshooting in order to optimize the outcomes. The goal of the present project is to develop a standardized and fully automated protocol that will provide the most comprehensive evaluation of lung physiology in a murine model of respiratory failure.
To whom the research is important? Our protocol will entitle non-respiratory experts to readily measure lung physiology with minimal mouse handling. On the short term, our project is thus essential for scientists who are specialized in the molecular and cellular aspects of infectious diseases but who need assistance to measure lung physiology in mice. On the long term, our project has the potential to improve patients' care and save lives by accelerating research and drug discovery on COVID-19
What are the anticipated outcomes and advancements that will result in benefits for Canada? A landmark protocol such as the one we aim to develop will ensure accuracy and reproducibility of the collected data. It will also facilitate comparisons between the tested drugs and the different laboratories. Additionally, it will promote a mature technology of a Canadian company, strengthen the link between an academic and a private sector, train highly qualified personnel and keep Canadian lung physiologists at the leading-edge of their field.
_x000d_Quelle est la nature du travail? Étant donné que 70% de la mortalité reliée à la COVID-19 est attribuée à une insuffisance respiratoire, les modèles murins d'insuffisance respiratoire deviendront de plus en plus utilisés afin de tester des drogues promett